$SENORES

Fundamental: Revenue +53.4% YoY | PAT +77.3% YoY | P/E 50.6x vs sector 46.4x (slight premium; near own 10Y avg) | Upside 22.2% | Operating Margin 34.2% (+987 bps) | ROCE 14.4% | Rank #5/51 peers | Rating 8.50 Technical: Strong bullish trend above all key MAs — 5/9/13 EMAs positively aligned | Consolidating near recent highs — HH-HL structure intact, strong underlying demand | Sustained move above ₹1,360 triggers next leg | RSI 72 — strong momentum, approaching overbought | ADX 44 — powerful trend confirmed | MACD positive territory — bullish outlook intact Moat: Niche US-focused generic pharma with a high-margin formulations portfolio — 34%+ operating margins and nearly 1,000 bps of margin expansion signal deep product differentiation and pricing power uncommon at this market cap. View: A perfect outlook score (10/10), explosive earnings trajectory, and a stock approaching ATH at 52W Index 95 — momentum is clearly in control with institutional accumulation continuing.